Intercept Pharmaceuticals (ICPT -0.4%) slips on average volume. Shares were down almost 2% before recovering after CymaBay Therapeutics announced encouraging results from a mid-stage stage study of fally liver disease candidate seladelpar.
Intercept's NASH candidate is obeticholic acid, in Phase 3 testing. It was approved in the EU in December 2016 for primary biliary cirrhosis.
Previously: Intercept Pharma's obeticholic acid OK'd in Europe for primary biliary cirrhosis (Dec. 14, 2016)